EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-term outcomes of a shortened triple-drug regimen for acute promyelocytic leukemia: A 5-year real-world, single-center experience

Yue Shang, Qiuyun Fang, Jinsong He, Jiesi Li, Chunlin Zhou, Yan Li, Kaiqi Liu, Guangji Zhang, Shuning Wei, Dong Lin, Xiaoyuan Gong, Benfa Gong und 7 weitere

Cancer Treatment and Research Communications · 2026 · 49 · 101489

DOI: 10.1016/j.ctarc.2026.101489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yue Shang und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have transformed acute promyelocytic leukemia (APL) into a highly curable malignancy. However, the optimal integration of cytoreductive chemotherapy and the management of patients with hyperleukocytosis and FLT3-ITD-mutated disease remain under active investigation. METHODS: We evaluated a "triple-drug" regimen incorporating ATRA, ATO, and anthracyclines for induction and consolidation, followed by maintenance with ATRA and ATO in 80 newly diagnosed APL patients. RESULTS: Three early deaths (3.8%) were caused by hemorrhage and infection. Among 77 evaluable patients, all achieved morphologic complete remission after induction with universal molecular remission achieved after two consolidation cycles. The 5-year overall survival was 96.3% (92.2%-100.0%) and event-free survival was 90.7% (84.3%-97.5%). Neither FLT3-ITD status nor the speed of molecular response during induction impacted long-term EFS. Four patients experienced late relapse, but all achieved a second molecular remission following re-initiation of the triple-drug regimen. During induction therapy, following anthracycline cessation, peripheral counts rebounded briskly: platelets climbed from < 25 to ≥ 50 × 10⁹/L in a median of 10 days (IQR 5-14), and WBC surpassed 1 × 10⁹/L within 0 days (IQR 0-2). CONCLUSION: This uniform triple-drug regimen yields rapid molecular clearance, durable survival and robust salvage, with acceptable toxicity.

Schlagwörter

Stichwörter der Autor:innen

Acute promyelocytic leukemiaAll-trans retinoic acidAnthracyclineArsenic trioxide

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China Stem Cell and Translational Research

Zitieren

APA

Shang, Y., Fang, Q., He, J., Li, J., Zhou, C., Li, Y., Liu, K., Zhang, G., Wei, S., Lin, D., Gong, X., Gong, B., Liu, Y., Liu, B., Wang, Y., Wei, H., Wang, J., Yan, Z., & Mi, Y. (2026). Long-term outcomes of a shortened triple-drug regimen for acute promyelocytic leukemia: A 5-year real-world, single-center experience. Cancer Treatment and Research Communications, 49, 101489. https://doi.org/10.1016/j.ctarc.2026.101489

Vancouver

Shang Y, Fang Q, He J, Li J, Zhou C, Li Y, et al. Long-term outcomes of a shortened triple-drug regimen for acute promyelocytic leukemia: A 5-year real-world, single-center experience. Cancer Treatment and Research Communications. 2026;49:101489. doi:10.1016/j.ctarc.2026.101489

BibTeX
@article{Shang2026,
  author = {Shang, Yue and Fang, Qiuyun and He, Jinsong and Li, Jiesi and Zhou, Chunlin and Li, Yan and Liu, Kaiqi and Zhang, Guangji and Wei, Shuning and Lin, Dong and Gong, Xiaoyuan and Gong, Benfa and Liu, Yuntao and Liu, Bingcheng and Wang, Ying and Wei, Hui and Wang, Jianxiang and Yan, Zhangsong and Mi, Yingchang},
  title = {Long-term outcomes of a shortened triple-drug regimen for acute promyelocytic leukemia: A 5-year real-world, single-center experience},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101489},
  doi = {10.1016/j.ctarc.2026.101489}
}
Kostenlos starten →